OTLK EBITDA | OUTLOOK THERAPEUTICS, INC.

OUTLOOK THERAPEUTICS, INC. (OTLK) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$10.81M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$14.03M; Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA (m); Operating income -$13.48M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$15.75M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2015-03-31 to 2020-09-30
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$10.81M	(m)	(m)	(m)	(m)	-$21.01M*	$16.96K	$3.25M	$7.55M	(m)
2026-03-31	Reported	(m)	-$14.03M	(m)	(m)	(m)	(m)	-$7.83M*	$149.33K	$4.50M	$9.50M	(m)
2025-12-31	Reported	(m)	-$13.48M	(m)	(m)	(m)	(m)	-$14.94M	$29.63K	$3.63M	$8.61M	(m)
2025-06-30	Reported	(m)	-$15.75M	(m)	$1.51M	(m)	(m)	-$11.90M*	$439.81K	$7.13M	$9.68M	$0.00*
2025-03-31	Reported	(m)	-$12.39M	(m)	(m)	(m)	(m)	-$16.58M*	(m)	$4.41M	$7.98M	$2.80K
2024-12-31	Reported	(m)	-$21.61M	(m)	(m)	(m)	(m)	-$10.97M	(m)	$9.66M	$11.95M	(m)
2024-06-30	Reported	(m)	-$19.56M	(m)	(m)	(m)	(m)	-$19.51M*	(m)	$11.20M	$8.36M	$0.00*
2024-03-31	Reported	(m)	-$18.94M	(m)	(m)	(m)	(m)	-$19.27M*	(m)	$13.51M	(m)	$2.80K
2023-12-31	Reported	(m)	-$10.32M	(m)	(m)	(m)	(m)	-$13.03M	(m)	$4.53M	(m)	(m)
2023-06-30	Reported	(m)	-$18.14M	(m)	(m)	(m)	(m)	-$13.22M*	(m)	$11.10M	(m)	$0.00*
2023-03-31	Reported	(m)	-$6.84M	(m)	(m)	(m)	(m)	-$8.11M*	(m)	$544.95K	(m)	$2.80K
2022-12-31	Reported	(m)	-$15.69M	(m)	(m)	(m)	(m)	-$8.90M	(m)	$9.86M	(m)	(m)
2022-06-30	Reported	(m)	-$17.02M	(m)	(m)	(m)	(m)	-$21.10M*	(m)	$11.25M	(m)	$0.00*
2022-03-31	Reported	(m)	-$18.91M	(m)	(m)	(m)	(m)	-$14.33M*	(m)	$12.22M	(m)	$2.00K
2021-12-31	Reported	(m)	-$13.15M	(m)	(m)	(m)	(m)	-$10.99M	(m)	$9.87M	(m)	(m)
2021-06-30	Reported	(m)	-$11.47M	(m)	(m)	(m)	(m)	-$20.19M*	(m)	$8.55M	(m)	$0.00*
2021-03-31	Reported	(m)	-$12.63M	(m)	(m)	(m)	(m)	-$11.75M*	(m)	$8.53M	(m)	$2.00K
2020-12-31	Reported	(m)	-$14.19M	(m)	(m)	(m)	(m)	-$13.32M	(m)	$11.95M	(m)	(m)
2020-09-30	Reported	-$9.97M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-06-30	Reported	-$11.83M	(m)	(m)	(m)	(m)	(m)	-$5.96M*	(m)	$8.49M	(m)	-$3.27M
2020-03-31	Reported	-$6.7M	(m)	(m)	(m)	(m)	(m)	-$7.08M*	(m)	$4.38M	(m)	(m)
2019-12-31	Reported	-$8.12M	(m)	(m)	(m)	(m)	(m)	-$6.67M	(m)	$5.85M	(m)	(m)
2019-09-30	Reported	-$11.8M	(m)	(m)	(m)	-201.64%	(m)	(m)	(m)	(m)	(m)	(m)
2019-06-30	Reported	-$4.81M	(m)	(m)	(m)	-823.98%	$150.74K*	-$10.31M*	(m)	$4.34M	(m)	-$777.50K
2019-03-31	Reported	-$6.89M	(m)	(m)	(m)	-1074.51%	$50.14K*	-$6.26M*	(m)	$5.94M	(m)	(m)
2018-12-31	Reported	-$9.43M	(m)	(m)	(m)	-883.69%	$236.43K	-$9.78M	(m)	$6.07M	(m)	(m)
2018-09-30	Reported	-$11.59M	(m)	(m)	(m)	-1501.41%	(m)	(m)	(m)	(m)	(m)	(m)
2018-06-30	Reported	-$6.4M	(m)	(m)	(m)	-828.85%	$168.02K*	-$8.54M*	(m)	$5.80M	(m)	$0.00*
2018-03-31	Reported	-$6.12M	(m)	(m)	(m)	-793.47%	$275.19K*	-$7.44M*	(m)	$5.16M	(m)	$0.00*
2017-12-31	Reported	-$2.5M	(m)	(m)	(m)	-324.29%	$1.08M	-$8.67M	(m)	$402.40K	(m)	-$3.15M
2017-09-30	Reported	-$2.24M	(m)	(m)	(m)	-77.20%	(m)	(m)	(m)	(m)	(m)	(m)
2017-06-30	Reported	-$6.66M	(m)	(m)	(m)	-2198.43%	$76.23K*	(m)	(m)	$4.16M	(m)	$0.00*
2017-03-31	Reported	-$7.16M	(m)	(m)	(m)	-2361.23%	$43.52K*	(m)	(m)	$4.12M	(m)	$0.00*
2016-12-31	Reported	-$17.13M	(m)	(m)	(m)	-5649.36%	$148.36K	(m)	(m)	$13.23M	(m)	$4.00K
2016-09-30	Reported	-$9.35M	(m)	(m)	(m)	-1889.07%	(m)	(m)	(m)	(m)	(m)	(m)
2016-06-30	Reported	-$21.43M	(m)	(m)	(m)	-4329.99%	$452.48K*	(m)	(m)	$12.02M	(m)	$500.00
2016-03-31	Reported	-$2.36M	(m)	(m)	(m)	-236.79%	-$46.95K*	(m)	(m)	$4.14M	(m)	$50.50K
2015-12-31	Reported	-$15.82M	(m)	(m)	(m)	-1590.04%	$364.24K	(m)	(m)	$12.73M	(m)	$52.00K
2015-09-30	Reported	-$16.41M	(m)	(m)	(m)	-3315.77%	(m)	(m)	(m)	(m)	(m)	(m)
2015-06-30	Reported	-$10.62M	(m)	(m)	(m)	-820.50%	$3.49M*	(m)	(m)	$9.68M	(m)	$120.00K
2015-03-31	Reported	-$13.78M	(m)	(m)	(m)	-2784.97%	(m)	(m)	(m)	$10.15M	(m)	-$726.22K

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-09-30	Reported	(m)	-$67.06M	(m)	$1.41M	(m)	(m)	-$51.83M	$1.36M	$27.18M	$39.94M	-$1.55M
2024-09-30	Reported	(m)	-$71.70M	(m)	(m)	(m)	(m)	-$68.79M	(m)	$41.76M	$29.94M	$2.80K
2023-09-30	Reported	(m)	-$53.13M	(m)	(m)	(m)	(m)	-$42.97M	(m)	$26.45M	(m)	$2.80K
2022-09-30	Reported	(m)	-$63.07M	(m)	(m)	(m)	(m)	-$56.67M	(m)	$42.33M	(m)	$2.80K
2021-09-30	Reported	(m)	-$51.73M	(m)	(m)	(m)	(m)	-$54.25M	(m)	$38.96M	(m)	$2.00K
2020-09-30	Reported	-$36.62M	(m)	(m)	(m)	(m)	(m)	-$31.79M	(m)	$26.34M	(m)	-$3.27M
2019-09-30	Reported	-$32.94M	(m)	(m)	(m)	-404.33%	$437.31K	-$32.29M	(m)	$23.81M	(m)	-$3.41M
2018-09-30	Reported	-$26.59M	(m)	(m)	(m)	-861.20%	$2.78M	-$33.04M	(m)	$18.50M	(m)	-$3.65M
2017-09-30	Reported	-$33.19M	(m)	(m)	(m)	-870.73%	$292.09K	-$15.51M	(m)	$23.81M	(m)	$501.50K
2016-09-30	Reported	-$48.95M	(m)	(m)	(m)	-1642.95%	$1.10M	(m)	(m)	$32.76M	(m)	$103.00K
2015-09-30	Reported	-$44.74M	(m)	(m)	(m)	-857.18%	$8.80M	(m)	(m)	$38.88M	(m)	-$190.11K

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Acumen Pharmaceuticals, Inc. (ABOS)	United States	$0.162B	-1.83
Humacyte, Inc. (HUMA)	United States	$0.155B	-2.26
Voyager Therapeutics, Inc. (VYGR)	United States	$0.173B	-1.99
PRECISION BIOSCIENCES INC (DTIL)	United States	$0.175B	-3.95
Coherus Oncology, Inc. (CHRS)	United States	$0.182B	-1.63
Tenaya Therapeutics, Inc. (TNYA)	United States	$0.140B	-1.60
Alpha Cognition Inc. (ACOG)		$0.185B	-6.77
Caribou Biosciences, Inc. (CRBU)	United States	$0.134B	-1.79
Armata Pharmaceuticals, Inc. (ARMP)	United States	$0.132B
Neumora Therapeutics, Inc. (NMRA)	United States	$0.132B	-1.48